Topical retinoid medications for acne - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About Topical retinoid medications for acne - [Medication] - Quest Diagnostics Patient Health Library Topical retinoid medications for acne - [Medication] - Quest Diagnostics Patient Health Library Skin, hair, and nails, Acne, acne treatment, Acne vulgaris, Adapalene, Differin...
Paragraph IV Patent Certifications - DRUG NAME DOSAGE FORM STRENGTH RLD Acetaminophen Extended-release Tablets 650 mg Tylenol Acetaminophen/ Aspirin/ Caffeine Tablets 250 mg/250 mg/ 65 mg Excedrin (migraine) Acetaminophen and Tramadol Hydrochloride Tablets 325 mg/ 37.5 mg Ultracet Acyclovir Sodium1 Injection 50 mg/mL, 10 mL and 20 mL vials Zovirax Albuterol Sulfate Oral Syrup 2 mg(base)/ 5 mL Ventolin Albuterol...
http://www.fda.gov/cder/orange/appendix_a.txt 4, ACETAMINOPHEN PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN PHENAZINE, PHENDIMETRAZINE TARTRATE PHENAZINE-35, PHENDIMETRAZINE TARTRATE PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE PHENERGAN W/ CODEINE, CODEINE...
2002 Warning Letters and Untitled Letters to Pharmaceutical Companies Food and Drug Administration • Center for Drug Evaluation and Research Compliance Activities Search Warning Letters and Untitled Letters to Pharmaceutical Companies 2002 These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office
author: STAUFFERP
Reference Listed Drug Labeling Approved in May 2002 -- COUMADIN letter -- warfarin Na tablet 09-218 SLR 098 - COUMADIN letter - warfarin Na tablet 09-218 SLR 099 May 3 DURICEF letter label cefadroxil monohydrate capsule 50-528 SLR 018 DURICEF letter label cefadroxil monohydrate suspension 50-527 SLR 020 DURICEF letter label cefadroxil monohydrate tablet 50-512 SLR 044 PREVACID letter label lansoprazole tablet 21-281 SLR 002 --...
author: USERNAME
FDA Drug Approvals List May 2002 - Drug Approvals for May 2002 Definitions and Notes Original New Drug Applications Original Abbreviated Antibiotic Application # 065082 Approval Date: 31-MAY-02 Trade Name: CEFPODOXIME PROXETIL Dosage Form: GRANULE, FOR RECONSTITUTION Applicant: RANBAXY LABORATORIES LTD Active Ingredient(s): CEFPODOXIME PROXETIL OTC/RX Status: RX Original Application #: 021292 Approval Date: 31-MAY...
Prescription and OTC Drug Product List 9/2002 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST -A- ADEFOVIR DIPIVOXIL -A- TABLET; ORAL -A- HEPSERA -A- + GILEAD 10MG N21449 001 SEP 20, 2002 SEP NEWA ALBUTEROL SULFATE TABLET, EXTENDED RELEASE; ORAL -A- ALBUTEROL SULFATE -A- AB SIDMAK LABS EQ 4MG BASE N76130 002 SEP 26, 2002 SEP NEWA -A- AB EQ 8MG BASE N76130 003 SEP 26, 2002 SEP NEWA VOLMAX -D- BC + MURO EQ 4MG BASE N19604...
8 Latyszonek: Please refer to your supplemental new drug application dated July 12, 2001, received July 12, 2001, submitted under section 505( b) of the Federal Food, Drug, and Cosmetic Act for Retin - A MICRO (tretinoin gel) microspheres, 0.04%tretinoin gel and is indicated for topical...
8 page 1
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf The mean reductions in lesion counts from baseline after treatment for 12 weeks are shown in the following table: Mean Percent Reduction in Lesion Counts Retin - A Micro (tretinoin gel) microsphere, 0.1% Retin - A Micro (tretinoin gel) microsphere, 0.1% Vehicle gel Study #1 72 pts Study #2 71 pts Study #1 72 pts Study #2 67 pts Non- inflammatory...
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 15
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 12
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 11
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 10
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 9
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 8
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 7
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 6
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 5
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 4
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 3
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 2
http://www.fda.gov/cder/foi/label/2002/20475s8lbl.pdf page 1
Prescription and OTC Drug Product List 12/1998 Prescription and Over-the-Counter Drug Product List - 18th Edition Cumulative Supplement Number 12: December 1998 [ Prescription - OTC ] ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST - ADD - ABACAVIR SULFATE ALBUTEROL SULFATE - ADD - SOLUTION; ORAL SOLUTION; INHALATION - ADD - ZIAGEN ALBUTEROL SULFATE - ADD - + GLAXO WELLCOME EQ 20MG BASE/ML N20978 001 - ADD - @ COPLEY PHARM...
February Drug Approvals Drug Approvals for February 1997 Definitions and Notes February 1997 Original New Drug Applications Original Application #: 020723 Approval Date: 27-FEB-97 Trade Name: ALDARA Chemical Type: 1 Therapeutic Potential: S Dosage Form: CREAM Applicant: 3M PHARMACEUTICALS INC Active Ingredient(s): IMIQUIMOD OTC/RX Status: RX Indication(s): Treatment of external genital and perianal warts...
